Results 1 to 10 of about 69,645 (303)
Thrombotic diseases and conditions – diagnosis and monitoring of anticoagulant therapy
Медицинский совет, 2021 Laboratory methods are a very important part of the examination of patients with thrombotic diseases, often putting the final touches on the diagnosis, and in some cases even defining this diagnosis.
A. L. Melkumyan +3 more
doaj +1 more source
罕见病研究, 2022 Hemophilia is a group of hereditary hemorrhagic diseases. Hemorrhages mostly occur in musculoskeletal system and is the main cause for disability. Rehabilitation plays an important role in the comprehensive management in hemophilia.
Hemophilia Treatment Center Collaborative Network of China +1 more
doaj +1 more source
Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
TH Open, 2021 Aim Very little is known regarding reproductive choices, pregnancy, and delivery of women with moderate to severe hemophilia. Our aim was to describe our experience with three hemophiliac women and their journey to achieve motherhood.
Shadan Lalezari +6 more
doaj +1 more source
Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
Clinics and Practice, 2021 Poor management of either type 1 diabetes or haemophilia A can lead to complications such as organ dysfunction and haemarthropathy. Here, we describe the case of an 8-year-old boy diagnosed with severe haemophilia A shortly after birth.
Maria Sol Cruz +4 more
doaj +1 more source
Hemophilia A with reduced coagulation factor Ⅺ: a case report and literature review
Zhongguo shuxue zazhi, 2023 Objective To investigate the possible molecular pathogenesis of a child with hemophilia A accompanied by coagulation factor Ⅺ reduction by testing coagulation-related indicators and genotyping in the child and his family.
Jie WANG +8 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products.
Beth Boulden Warren +9 more
doaj +1 more source
BMC Health Services Research, 2022 Background Hemophilia care in mainland China has been greatly improved since the establishment of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC), and most of drugs for hemophilia have been covered by basic medical insurance ...
Zhengwei Huang +6 more
doaj +1 more source
Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A
罕见病研究, 2022 Hemophilia A is an X-chromosome-linked recessive genetic disease that lacks coagulation factor Ⅷ (Factor Ⅷ, FⅧ) and is clinically manifested as spontaneous or excessive bleeding after injury.The current main treatment for hemophilia A is alternative ...
Hemophilia Treatment Center Collaborative Network of China
doaj +1 more source
Report on diagnosis and treatment of hemophilia in China 2023 [PDF]
Zhenduanxue lilun yu shijian, 2023 In recent years, China attaches great importance to the prevention and treatment of rare diseases. As one of the representative diseases of rare diseases, management of Hemophilia has made great progress in China.
XUE Feng, DAI Jing, CHEN Lixia, LIU Wei, ZHANG Houqiang, WU Runhui, SUN Jing, ZHANG Xinsheng, WU Jingsheng, ZHAO Yongqiang, WANG Xuefeng, YANG Renchi
doaj +1 more source